CJC-1295 + Ipamorelin Research Stack
Research compounds — not for human consumption
Growth / Regeneration Research Stack — CJC-1295 + Ipamorelin
Both compounds supplied together as a single research stack — priced below buying each separately.
Overview
CJC-1295, a growth-hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective growth-hormone secretagogue that acts as a ghrelin-receptor (GHS-R1a) agonist, are one of the most frequently studied pairings in growth-hormone-axis research. The combination is of interest because the two compounds act on two different receptors within the same signaling system.
Compounds in this stack
Areas of Combined Research Interest
GHRH analogs such as CJC-1295 are studied for their influence on the amplitude of growth-hormone pulses via the GHRH receptor, while selective secretagogues such as Ipamorelin are studied for their action at the ghrelin receptor and for their selectivity relative to earlier secretagogues. Research interest in the combination focuses on the complementary-pathway question — whether simultaneous stimulation of the GHRH receptor and the ghrelin receptor produces additive effects on growth-hormone release in cell and animal models — and on characterizing Ipamorelin's receptor selectivity. As with other combinations, the most rigorous data addresses each compound individually.
Storage & Handling
Both compounds are typically supplied as lyophilized powder and, in research settings, are stored sealed and protected from light, with reconstituted solutions kept refrigerated. Handle per standard laboratory practice.
References
References are provided for scientific context. Combination-specific data is limited; most published research characterizes each compound individually. Linked sources are independent and not affiliated with iNGEN MD.